v3.25.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net loss $ (1,945,573) $ (3,116,563)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Accrued interest 2,947 27,283  
Amortization of original issue discount and debt issuance costs 1,171,465  
Change in fair value of liability classified warrants (9,916) (8,955)  
Consultant compensation 46,093  
Stock-based compensation 16,251 33,207  
Changes in operating assets and liabilities:      
Unbilled receivable 102,113 1,337  
Prepaid expenses and other assets 433,659 (86,697)  
Accounts payable (741,784) (1,295,655)  
Accrued expenses and other liabilities 388,798 (133,825)  
Net cash used in operating activities (1,707,412) (3,408,403)  
Cash flows from financing activities:      
Proceeds from public offerings 1,100,006  
Proceeds from warrant exercises 347,995 2,075,219  
Proceeds from warrant inducement, net of issuance costs 4,718,295  
Transaction costs from public offerings (142,950)  
Transaction costs associated with warrant inducements (465,494)  
Repayment of convertible notes (485,190)  
Repayment of financed insurance premiums (47,225) (153,682)  
Net cash provided by financing activities 1,257,826 5,689,148  
Increase (decrease) in cash and cash equivalents (449,586) 2,280,745  
Cash and cash equivalents beginning of period 3,502,077 1,123,604 $ 1,123,604
Cash and cash equivalents end of period 3,052,491 3,404,349 $ 3,502,077
Supplemental disclosure of non-cash investing and financing activities:      
Incremental fair value of February 2024 Warrant Inducement 5,167,372  
Conversion of convertible notes into common stock 1,168,600  
Transaction costs from warrant inducement 341,368  
Transaction costs from public offerings 61,243  
Deemed dividend related to warrants down round provision $ 290  

Source

PDF HTML
ZIP XLS XBRL